Lupin has received final USFDA approval to market Budesonide Inhalation Suspension single-dose ampoules, used for treating Asthma in the American markets.
The drug is a generic version of AstraZeneca Pharmaceuticals LP’s Pulmicort Respules Inhalation Suspension, 0.5 mg/2 million. According to market estimates, the Asthma drug had annual sales of around $ 474.5 million in the US.
Company Profile : Lupin Ltd
Leave a Reply